[Kert Gartner]’s ASCII Aquarium turns a cheap yellow display (CYD) into a tiny simulated aquarium, complete with ASCII sea creatures each with their own behaviors. There’s all kinds of options and ...

If you've ever wanted to integrate OpenAI's ChatGPT features into your Java programs, you'll be happy to learn that Spring AI has made the process easier than ever. And it's not just easier to connect ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Generate:Biomedicines' anti-TSLP antibody GB-0895 is currently being evaluated in a pair of phase 3 studies for severe asthma. (Stock photo/Getty Images) Clinical-stage antibody company ...

Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...